Marcacci, Gianpaolo
Coppola, Nicola
Madonna, Emanuela
Becchimanzi, Cristina
De Pascalis, Stefania
D’Ovidio, Silvia
Crisci, Stefania
Maiolino, Piera
De Filippi, Rosaria
Pinto, Antonio
Funding for this research was provided by:
Supported in part by Ministero della Salute, Ricerca Corrente IRCCS, Rome, Italy
Article History
Received: 7 June 2022
Accepted: 22 July 2022
First Online: 3 August 2022
Declarations
:
: The patient signed a written informed consent to off-label treatment with sotrovimab. All transplanted patients have signed a written informed consent (EBMT-F-023-01) allowing use of anonymized registered clinical data for scientific purposes. All clinical procedures were performed in accordance to the 1964 Helsinki declaration.
: A further written informed consent has been obtained from patient 2 for clinical data collection, elaboration and publication of the present report.
: The authors declare that they have no competing interests.